Ripretinib
Overview
Ripretinib is a tyrosine kinase inhibitor used in the treatment of advanced gastrointestinal stromal tumors (GIST) after disease progression on other kinase inhibitors. It works by inhibiting multiple kinases involved in tumor growth.
API suppliers (1)
Suppliers of Ripretinib evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
- DR REDDYS LABORATORIES LTD1 active DMF GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Ripretinib expires 6 Oct 2042 and exclusivity 15 May 2027. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Ripretinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.